Welcome to our dedicated page for Ernexa news (Ticker: ERNA), a resource for investors and traders seeking the latest updates and insights on Ernexa stock.
Ernexa Therapeutics develops cell therapies for advanced cancer and autoimmune disease using engineered induced pluripotent stem cells that are transformed into synthetic allogeneic induced mesenchymal stem cells. News about the company centers on ERNA-101, its lead iMSC candidate for ovarian cancer, including preclinical tumor-model results, immuno-oncology combinations and scientific discussions of the ovarian cancer treatment landscape.
Company updates also cover ERNA-201 for autoimmune inflammation, regulatory interactions tied to cell-therapy development, investor presentations, collaboration or market-entry programs, and capital-structure actions such as common-stock reverse splits and Nasdaq listing compliance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eterna Therapeutics Inc. (ERNA) has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC for up to $10 million. This arrangement allows LPC to purchase shares at Eterna's discretion over a 24-month period, starting upon certain conditions being met, including an effective registration statement with the SEC. The price per share will be based on prevailing market prices at the time of each sale. Notably, LPC has agreed to refrain from short selling or engaging in hedging of Eterna's stock. Eterna retains complete control over the timing and amount of share sales and can terminate the agreement at any time without penalty. CEO Matt Angel stated this agreement enhances financial flexibility to support the development of next-generation mRNA therapies, leveraging the company’s extensive patent portfolio.
Eterna Therapeutics (Nasdaq: ERNA) has appointed Jeff Karp, Ph.D., to its Scientific Advisory Board. Dr. Karp, an esteemed scientist and entrepreneur, brings extensive expertise in drug delivery and cell therapeutics, aiming to advance Eterna’s mRNA cell engineering platform. CEO Matt Angel highlighted Dr. Karp's successful track record and innovation in biomedical products. Dr. Karp expressed enthusiasm about contributing to Eterna's mission to develop transformative mRNA-based therapies. The company holds over 100 patents relating to key mRNA technologies, including gene editing and delivery systems.
Eterna Therapeutics Inc. (Nasdaq: ERNA) has made significant strides in their financial results for 2022, reporting a net loss of $24.6 million, or $8.06 per share. Key highlights include an exclusive income-generating agreement with Lineage Cell Therapeutics for developing gene-edited iPSC therapies, and a sublease for 45,000 sq. ft. at Cambridge Crossing from Bristol Myers Squibb. R&D expenses totaled $10.4 million for the year, with general and administrative costs at $16.8 million. Eterna ended 2022 with approximately $15.5 million in cash. The company continues to leverage its mRNA cell engineering patent portfolio, positioning itself for future growth.